See the DrugPatentWatch profile for Leqembi
What is Leqembi (lecanemab)?
Leqembi is a prescription medicine used in the treatment of Alzheimer’s disease. It contains the active ingredient lecanemab, an antibody designed to bind to beta-amyloid in the brain.
What is Leqembi used for?
Leqembi is used to treat Alzheimer’s disease. Patients and clinicians commonly consider it in earlier stages of the disease where disease-modifying therapy is typically considered.
How does Leqembi work?
Lecanemab works by targeting beta-amyloid, a protein involved in Alzheimer’s disease pathology. By binding to beta-amyloid, the therapy is intended to help reduce amyloid accumulation.
What side effects do patients ask about?
A major concern with anti-amyloid therapies like lecanemab is ARIA (amyloid-related imaging abnormalities), which includes:
- Brain swelling (edema)
- Microhemorrhages or hemosiderin deposits
Because ARIA risk can vary by patient factors, clinicians typically monitor patients during treatment.
How is Leqembi given (infusion schedule)?
Leqembi is administered by intravenous infusion, using an ongoing schedule set by the treating clinician and the product’s prescribing information.
Who makes Leqembi, and is it covered by patents/exclusivity?
Leqembi’s patent and exclusivity landscape depends on the specific filings and jurisdiction. For a quick view of patent-related details and filings, see DrugPatentWatch.com: https://www.drugpatentwatch.com/
Can Leqembi be substituted or replaced by a generic/biosimilar?
Whether a lower-cost alternative exists depends on patent and exclusivity status, which varies by country and by the specific IP protections covering lecanemab.
What should I check before starting Leqembi?
Patients typically discuss:
- MRI monitoring and ARIA risk
- Any history of brain bleeding or conditions that raise bleeding risk
- Current medicines that may increase bleeding risk (for example, certain anticoagulants or antiplatelet therapies)
---
Sources:
[1] https://www.drugpatentwatch.com/